The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: * Prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone, provided a stable regimen has been maintained for at least 4 weeks prior to study entry. Patients must have: * HIV seropositivity. * CD4 count \>= 100 cells/mm3. * p24 antigen (immune-complex dissociated) \>= 50 pg/ml. * Life expectancy of at least 6 months. Prior Medication: Allowed: * Prior prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole, trimethoprim/sulfamethoxazole, or dapsone. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active, serious infection (other than HIV infection) requiring parenteral antibiotic therapy. * Malignancy other than cutaneous Kaposi's sarcoma. * Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. * Gastrointestinal malabsorption syndrome. * Inability to take oral medication. Concurrent Medication: Excluded: * Any parenteral antibiotic therapy. * Diuretics. * Amphotericin B. * Didanosine (ddI). * Fluconazole. * Foscarnet. * Ganciclovir. * Interferon-alpha. * Interferon-beta. * Isoniazid. * Aminoglycoside antibiotics. * Ketoconazole (topical allowed). * Itraconazole. * Rifabutin. * Rifampin. * Stavudine (d4T). * Zalcitabine (ddC). * Zidovudine (AZT). * Lamivudine (3TC). * Any investigational agents (except with sponsor approval). * Systemic therapy for Kaposi's sarcoma. Patients with the following prior condition are excluded: History of lactose intolerance. Prior Medication: Excluded within 2 weeks prior to study entry: * Any parenteral antibiotic therapy. * Diuretics. * Amphotericin B. * Didanosine (ddI). * Fluconazole. * Foscarnet. * Ganciclovir. * Interferon-alpha. * Interferon-beta. * Isoniazid. * Aminoglycoside antibiotics. * Ketoconazole (topical allowed). * Itraconazole. * Rifabutin. * Rifampin. * Stavudine (d4T). * Zalcitabine (ddC). * Zidovudine (AZT). * Lamivudine (3TC). * Any investigational agents (except with sponsor approval). Excluded within 4 weeks prior to study entry: Systemic therapy for Kaposi's sarcoma. Active substance abuse (including alcohol) as determined by questionnaire or positive drug screen.